Install
Nephrology & Urology
Kidneys, dialysis, stones, infections, prostate, and continence concerns.
- 5 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
- Cardiology & Metabolic Health
- Oncology & Hematology
- Neurology & Neuroscience
- Orthopedics & Sports Medicine
- Respiratory & Pulmonology
- Gastroenterology & Hepatology
- Endocrinology & Hormones
- Dermatology
- Rheumatology & Autoimmune
- OB‑GYN (Women’s Health)
- Pediatrics & Adolescent Health
- Geriatrics & Healthy Aging
- Ophthalmology & Vision
- ENT (Ear, Nose & Throat)
- Dentistry & Oral Health
Latest in Nephrology & Urology
Goldman Urology Surpasses 6,500 BPH Procedures, Expanding Individualized Treatment Strategies
3+ hour, 6+ min ago (467+ words) 11 Doctors Across Five Branches Three Urologists Performing BPH Surgery Goldman Urology Gangnam Branch Multiple Treatment Options for Different Patient Needs Goldman Urology provides five major procedural and surgical options for BPH: holmium laser enucleation of the prostate (HoLEP), Aquablation, Rezūm…...
Health minister urges men to discuss prostate cancer screening with doctors – Cyprus Inform
2+ hour, 29+ min ago (276+ words) Health Minister Neophytos Charalambides urged men to seek medical advice on prostate cancer screening, citing 726 new cases recorded annually in Cyprus. Nicosia, Cyprus. Health Minister Neophytos Charalambides called on men to seek medical advice on prostate cancer screening during a…...
Mohs Surgery Shows Similar Five-Year CSCC Recurrence Rates
4+ hour, 17+ min ago (262+ words) MMS is a tissue-sparing approach that provides complete margin control and is therefore theoretically expected to reduce recurrence. However, prospective comparisons with SE remain limited, and no randomised controlled trials have compared the approaches. In clinical practice, MMS is also…...
Dr. Ronald M. Clearie Joins New Jersey Urology, an Affiliate of U.S. Urology Partners
1+ hour, 58+ min ago (220+ words) VOORHEES, N.J., September 15, 2026--(BUSINESS WIRE)--New Jersey Urology is pleased to announce that Dr. Ronald M. Clearie has joined the practice. Dr. Clearie provides comprehensive urologic care and will support patients with a wide range of urologic needs, reflecting New Jersey Urology's…...
Walden Biosciences Announces CMO Appointment and Upcoming Clinical Data for WAL0921 in Proteinuric Chronic Kidney Disease
2+ hour, 7+ min ago (499+ words) Rekha Abichandani, M.D., appointed Chief Medical Officer Enrollment nearing completion in Phase 2 basket study of WAL0921; initial data from diabetic kidney disease cohorts to be presented in fourth quarter 2026 Data from Phase 1+ study of WAL0921 to be presented at American Society of Nephrology…...
Health minister urges men to seek early prostate cancer screening
2+ hour, 35+ min ago (243+ words) Health Minister Neophytos Charalambides called on men to seek medical advice on prostate cancer screening. Speaking at the Europa Uomo event marking European prostate cancer awareness day on Tuesday, Charalambides said prostate cancer remained “accompanied by embarrassment, fear, or the…...
NephroPlus Launches NIDA – NephroPlus International Dialysis Academy – to Build a Global Pipeline of Dialysis-Trained Nurses
3+ hour, 13+ min ago (15+ words) ...
Biomarker selection in APMN Prostate Cancer - Himisha Beltran & Joshua Lang
11+ hour, 15+ min ago (964+ words) Himisha Beltran and Joshua Lang discuss biomarker testing for newly diagnosed metastatic prostate cancer. Both agree BRCA2 alterations offer the strongest, most reproducible signal for upfront PARP inhibitor therapy, while genes such as ATM warrant a risk-benefit discussion. Dr. Lang cautions…...
New treatment to help ease effects of prostate problems
13+ hour, 3+ min ago (10+ words) Nine.com.au...
Dealroom.co | Janux doses first patient in Phase 1 trial of prostate cancer immunotherapy JANX013
6+ hour, 14+ min ago (257+ words) Janux doses first patient in Phase 1 trial of prostate cancer immunotherapy JANX013 Dealroom Janux doses first patient in Phase 1 trial of prostate cancer immunotherapy JANX013 What's happened: On 14 September 2026, Janux Therapeutics, a clinical-stage biotechnology company based in San Diego, announced that the…...